File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab

TitleRegular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab
Authors
KeywordsAlemtuzumab
Cytomegalovirus reactivation
Issue Date2007
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/35105
Citation
American Journal Of Hematology, 2007, v. 82 n. 2, p. 108-111 How to Cite?
AbstractTen patients with refractory lymphomas or autoimmune cytopenias were treated with alemtuzumab, and monitored prospectively for cytomegalovirus (CMV) reactivation by antigenemia and polymerase chain reaction. All patients showed virologic CMV reactivation. Two patients developed pneumonitis and hepatitis respectively, necessitating alemtuzumab withdrawal. Eight patients were asymptomatic, and with pre-emptive anti-CMV treatment, alemtuzumab therapy was uninterrupted. All patients ultimately achieved virologic remission. The frequent CMV reactivation was due to a high background seropositivity rate for CMV, severely immunocompromized patients, a sensitive detection method, and the diligence of surveillance. Frequent monitoring for and early treatment of CMV reactivation is necessary during alemtuzumab therapy. © 2006 Wiley-Liss, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/78473
ISSN
2015 Impact Factor: 5.0
2015 SCImago Journal Rankings: 1.761
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorCheung, WWen_HK
dc.contributor.authorTse, Een_HK
dc.contributor.authorLeung, AYHen_HK
dc.contributor.authorYuen, KYen_HK
dc.contributor.authorKwong, YLen_HK
dc.date.accessioned2010-09-06T07:43:17Z-
dc.date.available2010-09-06T07:43:17Z-
dc.date.issued2007en_HK
dc.identifier.citationAmerican Journal Of Hematology, 2007, v. 82 n. 2, p. 108-111en_HK
dc.identifier.issn0361-8609en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78473-
dc.description.abstractTen patients with refractory lymphomas or autoimmune cytopenias were treated with alemtuzumab, and monitored prospectively for cytomegalovirus (CMV) reactivation by antigenemia and polymerase chain reaction. All patients showed virologic CMV reactivation. Two patients developed pneumonitis and hepatitis respectively, necessitating alemtuzumab withdrawal. Eight patients were asymptomatic, and with pre-emptive anti-CMV treatment, alemtuzumab therapy was uninterrupted. All patients ultimately achieved virologic remission. The frequent CMV reactivation was due to a high background seropositivity rate for CMV, severely immunocompromized patients, a sensitive detection method, and the diligence of surveillance. Frequent monitoring for and early treatment of CMV reactivation is necessary during alemtuzumab therapy. © 2006 Wiley-Liss, Inc.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/35105en_HK
dc.relation.ispartofAmerican Journal of Hematologyen_HK
dc.subjectAlemtuzumaben_HK
dc.subjectCytomegalovirus reactivationen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAntibodies, Monoclonal - administration & dosage - adverse effectsen_HK
dc.subject.meshAntibodies, Monoclonal, Humanizeden_HK
dc.subject.meshAntibodies, Neoplasm - administration & dosage - adverse effectsen_HK
dc.subject.meshAntigens, Viral - blooden_HK
dc.subject.meshAntineoplastic Agents - administration & dosage - adverse effectsen_HK
dc.subject.meshAutoimmune Diseases - blood - complications - drug therapy - virologyen_HK
dc.subject.meshCytomegalovirusen_HK
dc.subject.meshCytomegalovirus Infections - blood - chemically induced - prevention & controlen_HK
dc.subject.meshDNA, Viral - blooden_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshImmunocompromised Host - drug effectsen_HK
dc.subject.meshLymphoma - blood - complications - drug therapy - virologyen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshMonitoring, Physiologic - methodsen_HK
dc.subject.meshPancytopenia - blood - complications - drug therapy - virologyen_HK
dc.subject.meshVirus Activation - drug effectsen_HK
dc.titleRegular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumaben_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0006-4971&volume=82&issue=2&spage=108&epage=11&date=2007&atitle=Regular+virologic+surveillance+showed+very+frequent+cytomegalovirus+reactivation+in+patients+treated+with+alemtuzumaben_HK
dc.identifier.emailTse, E:ewctse@hku.hken_HK
dc.identifier.emailLeung, AYH:ayhleung@hku.hken_HK
dc.identifier.emailYuen, KY:kyyuen@hkucc.hku.hken_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.authorityTse, E=rp00471en_HK
dc.identifier.authorityLeung, AYH=rp00265en_HK
dc.identifier.authorityYuen, KY=rp00366en_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/ajh.20780en_HK
dc.identifier.pmid17013817-
dc.identifier.scopuseid_2-s2.0-33846524272en_HK
dc.identifier.hkuros133604en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33846524272&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume82en_HK
dc.identifier.issue2en_HK
dc.identifier.spage108en_HK
dc.identifier.epage111en_HK
dc.identifier.isiWOS:000243573600003-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridCheung, WW=8615134400en_HK
dc.identifier.scopusauthoridTse, E=7005019454en_HK
dc.identifier.scopusauthoridLeung, AYH=7403012668en_HK
dc.identifier.scopusauthoridYuen, KY=36078079100en_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats